Cite
HARVARD Citation
Wei, A. et al. (2023). Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo‐controlled, phase 3 QUAZAR AML‐001 trial. American journal of hematology. 98 (4), pp. E84-E87. [Online].